HEMO (HEMO) News
Follow HEMO (HEMO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
UK's Hemogenyx Pharmaceuticals H1 loss widens on share-based payments
OverviewOutlookResult DriversCompany press release:Key DetailsReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact re
NEWS | Sep 28, 2026, 06:11 AM UTC
L
Hemogenyx Pharmaceuticals plc (HEMO) Reports H1 Loss £6.56M, Cash £4.58M
Hemogenyx Pharmaceuticals plc reported an unaudited H1 2026 loss before tax of £6.56M on operating costs of £6.48M, and cash of £4.58M. The company raised £5.6M during H1 and plans adult dose escalation and a pediatric a
NEWS | Sep 28, 2026, 06:01 AM UTC
L
Hemogenyx Pharmaceuticals PLC Announces Half-year Financial Report
Half-year ReportInterim Results for the period ended 30 June 2026LONDON, UK / / September 28, 2026 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the"Company") LSE:HEMO, the biopharmaceutical group devel
NEWS | Sep 28, 2026, 06:01 AM UTC
L
Hemogenyx Pharma issues equity after exercise of warrants
Hemogenyx Pharmaceuticals PLC says warrants were exercised and new equity was issued, via a regulatory RNS dated 3 September 2026.
EQUITY | Sep 03, 2026, 06:00 AM UTC
L
Hemogenyx exercises warrants, issues new equity shares
Hemogenyx Pharmaceuticals PLC announced the exercise of warrants and the issue of equity.
EQUITY | Sep 03, 2026, 06:00 AM UTC